About BridgeLine
We Started BridgeLine Because We Kept Seeing the Same Problems
So we built a firm that helps biotech companies get the strategy, the plan, and the story right before the diligence call comes.
Weak preclinical plans killing strong science
Teams running the wrong study first, using the wrong model, or building evidence packages that don’t answer the questions that matter.
Companies not ready when diligence came calling
Investors and pharma BD teams asking questions the company couldn’t answer clearly. Gaps that could have been closed months earlier.
Wrong indications chosen before the data could guide them
Programs locked into indications based on academic interest rather than competitive positioning, feasibility, and commercial potential.
Timothy S. Luongo, PhD, MSTR
Founder and Principal
Tim helps early-stage biotech teams translate complex biology into decision-grade development strategy and diligence-grade narratives. He partners with founders and R&D leaders to build IND-aligned preclinical plans that stand up to investor, partner, and regulatory scrutiny, and supports execution through clear decision criteria, CRO-ready study designs, timelines, and risk mitigation.
He brings this perspective from both sides of the table. In biotech, he designed and executed IND-enabling preclinical programs across genetic medicines and biologics at Spark Therapeutics (a Roche subsidiary), Sarepta Therapeutics, andStrideBio. On the buy-side, he evaluated companies as potential acquisition and partnership targets, supporting due diligence on transactions valued up to $11B, and managed external innovation partnerships: sourcing, assessing, and advancing opportunities aligned to portfolio strategy.
Earlier in his career, he worked at Cephalon (now Teva) and trained at Temple University, the NIH Vaccine Research Center, and the University of Pennsylvania, generating mechanistic and translational insights published in high-impact journals including Nature, Cell, Immunity, and Circulation. He holds a PhD from Temple University, a Master of Science in Translational Research (Regulatory Affairs and Drug Development) from UPenn, and a BS in Biochemistry from Eastern University.
Today, he uses that combined foundation to clarify what the data truly shows, what it doesn't, and what evidence is needed next, so teams can make confident program decisions and communicate them credibly to investors and partners.
What a Development Plan Covers
Four integrated workstreams, each built to a level of detail that holds up under investor and regulatory scrutiny.
Unmet Need & Positioning
We start by pressure-testing your thesis: target rationale, indication selection, competitive dynamics, and the strategic case an acquirer or investor would evaluate. This anchors every downstream decision.
Preclinical Roadmap
Each study is specified with model rationale, endpoint design, success criteria, budget, and CRO recommendations. The result is a protocol-level plan sequenced from current data through IND-enabling.
Path to Clinic
Regulatory strategy covers IND/CTA pathway, dose rationale using MABEL/NOAEL frameworks, pre-IND meeting preparation, and a nonclinical submission outline. We translate the science into regulatory-ready documentation.
Boardroom-Ready Deliverables
Risk registers, gap analysis, visual timelines, and executive summaries structured so your board, investors, or pharma partners can evaluate the program without a translation layer.
How We Work
What makes BridgeLine different from other consulting options.
Operator-to-Acquirer Lens
Tim has designed IND-enabling preclinical programs and evaluated companies from the acquirer’s side. Every deliverable is built to answer the questions investors and pharma BD teams actually ask.
Founder-Led, Every Engagement
Work is led directly by Tim. No junior handoff. No layered communication chain between strategy and decision-maker. The person doing the analysis is the person on the call.
Presentation-Ready Output
Visual timelines, detailed budget tables, executive summaries, and risk assessments, structured for immediate use in board meetings, investor presentations, and data rooms.
What a New Client Can Expect
- Complimentary Strategy Call to understand your program and recommend the right engagement
- Clear scope, timeline, and deliverables before any commitment
- Presentation-ready deliverables for board meetings and investor conversations
Why Companies Choose BridgeLine
vs. Hiring a Head of Preclinical or R&D
VP-quality decisions at a fraction of the cost · No 4-6 month recruiting cycle · Starts within 2 weeks
vs. Big Consulting Firms
Protocol-level specificity with CRO shortlists · Delivered by someone who has actually designed and executed IND-enabling programs
vs. CROs
CROs execute your studies · BridgeLine decides which studies to run and in what order · Cross-program optimization with no conflict of interest
vs. Doing It Internally
Makes sense if someone on your team has designed IND-enabling programs and evaluated programs from the acquirer’s side · If not, a diagnostic is a fast way to get that perspective
What Clients and Colleagues Say
From leaders at Parallel Bio, Lilly, Bound Therapeutics, and Sarepta Therapeutics.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Ready to Talk About Your Program?
Book a Strategy Call. Complimentary, 30 minutes, no obligation.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com